Epidermal growth factor radiopharmaceuticals:: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharacokinetics, and in vivo imaging of experimental brain tumors

被引:63
作者
Kurihara, A [1 ]
Deguchi, Y [1 ]
Pardridge, WM [1 ]
机构
[1] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA
关键词
D O I
10.1021/bc980123x
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Epidermal growth factor (EGF) is a potential peptide radiopharmaceutical for detection of brain tumors, because many human gliomas overexpress the EGF receptor (EGFR). The transport of EGF to the brain, however, is restricted by the blood-brain barrier (BBB). The purpose of the present study was to develop a vector-mediated brain delivery system for radiolabeled EGF. Human EGF was monobiotinylated with NHS-PEG(3400)-biotin, where NHS is N-hydroxysuccinimide and PEG(3400) is poly(ethylene glycol) of 3400 Da molecular mass. EGF-PEG(3400)-biotin was radiolabeled with either I-125 or In-111 through the metal chelator, diethylenetriaminepentaacetic acid (DTPA). The radiolabeled EGF was then conjugated to a BBB delivery vector comprised of a complex of the OX26 monoclonal antibody (MAb) to the rat transferrin receptor, which was coupled to streptavidin (SA). Following intravenous injection in rats, the I-125 conjugate was rapidly degraded in vivo, while the In-111 conjugate was metabolically stable. The brain delivery of [In-111]DTPA-EGF-PEG(3400)-biotin was enabled by conjugation with OX26/SA and was optimized by co-injection of unlabeled EGF to saturate EGF receptors in the liver. The specific binding of the [In-111]DTPA-EGF-PEG(3400)-biotin conjugated to OX26/SA to the EGF receptor was confirmed in C6 rat glioma cells, which had been transfected with a gene encoding for the human EGF receptor under the regulation of a dexamethasone-inducible promoter. In vivo studies of CG-EGFR experimental tumors in Fischer 344 rats demonstrated successful brain imaging only when the peptide radiopharmaceutical was conjugated to the BBB delivery system, although the C6-EGFR tumors did not express EGFR in vivo. In conclusion, these studies describe the molecular formulation of a peptide radiopharmaceutical that can be used for imaging brain tumors behind the BBB.
引用
收藏
页码:502 / 511
页数:10
相关论文
共 23 条
  • [1] IN-VIVO DEMONSTRATION OF SUBCELLULAR-LOCALIZATION OF ANTITRANSFERRIN RECEPTOR MONOCLONAL ANTIBODY-COLLOIDAL GOLD CONJUGATE IN BRAIN CAPILLARY ENDOTHELIUM
    BICKEL, U
    KANG, YS
    YOSHIKAWA, T
    PARDRIDGE, WM
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1994, 42 (11) : 1493 - 1497
  • [2] BLASBERG RG, 1986, SEMIN ONCOL, V13, P70
  • [3] Radiolabeling of epidermal growth factor with Tc-99m and in vivo localization following intracerebral injection into normal and glioma-bearing rats
    Capala, J
    Barth, RF
    Bailey, MQ
    Fenstermaker, RA
    Marek, MJ
    Rhodes, BA
    [J]. BIOCONJUGATE CHEMISTRY, 1997, 8 (03) : 289 - 295
  • [4] Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker
    Deguchi, Y
    Kurihara, A
    Pardridge, WM
    [J]. BIOCONJUGATE CHEMISTRY, 1999, 10 (01) : 32 - 37
  • [5] FENSTERMAKER RA, 1995, LEUKEMIA, V9, pS106
  • [6] Gibaldi M. P., 1982, PHARMACOKINETICS
  • [7] OPENING THE BLOOD-BRAIN AND BLOOD TUMOR BARRIERS IN EXPERIMENTAL RAT-BRAIN TUMORS - THE EFFECT OF INTRACAROTID HYPEROSMOLAR MANNITOL ON CAPILLARY-PERMEABILITY AND BLOOD-FLOW
    HIESIGER, EM
    VOORHIES, RM
    BASLER, GA
    LIPSCHUTZ, LE
    POSNER, JB
    SHAPIRO, WR
    [J]. ANNALS OF NEUROLOGY, 1986, 19 (01) : 50 - 59
  • [8] The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
    Huang, HJS
    Nagane, M
    Klingbeil, CK
    Lin, H
    Nishikawa, R
    Ji, XD
    Huang, CM
    Gill, GN
    Wiley, HS
    Cavenee, WK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (05) : 2927 - 2935
  • [9] KANG YS, 1994, J PHARMACOL EXP THER, V269, P344
  • [10] KIM DC, 1989, BIOCHEM PHARMACOL, V38, P241